Targeting both CCL2/CCR2 and CSF-1/CSF-1R axis is therefore relevant to a tumor that overexpresses M-CSF, CCL2 and other chemokines that bind to CCR2 such as CCL7. The gene discussed is CCL2; the disease is neoplasm.